2509447-07-6
2509447-07-6 structure
- Name: Amubarvimab
- Chemical Name: Amubarvimab
- CAS Number: 2509447-07-6
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Anti-infection SARS-CoV
- Create Date: 2023-01-14 22:20:49
- Modify Date: 2024-01-16 19:25:49
-
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants[1][2].
| Name | Amubarvimab |
|---|
| Description | Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Amubarvimab 对野生型 SARS-CoV-2 具有特异性活性，并且与其他冠状病毒无交叉反应[1]。 Amubarvimab 结合两个区域，跨越受体结合基序 (RBM) 中的氨基酸 453-505 和 RBD 核心区域中的氨基酸残基 403-421[1]。 |
| In Vivo | Amubarvimab (10-50 mg/kg; i.p.) 与 Romusevimab 联合给药可显着降低 SARS-CoV-2 感染的叙利亚金仓鼠肺部病毒载量，并减轻肺部病变[1]。 |
| References |
[2]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drug. 2022 Aug;82(12):1327-1331. |
| No Any Chemical & Physical Properties |